November 30, 2018
International World AIDS Day will be celebrated on 1 December 2018. The goal of the day is to support those living with HIV and those close to them and by adding information prevention and treatment of HIV. The World AIDS Day is also a day to remember those who have died of AIDS and it has been celebrated since 1988.
“With medication, people with HIV can live their lives without symptoms. However, there is a need for a safer and more cost-effective alternative to current HIV therapies. We are developing a new therapy, which may be an alternative to conventional therapy with antiviral drugs. Our objective is to offer people living with HIV a cost-effective, efficacious and safe treatment with no need for daily intake of antiviral drugs”, says FIT Biotech’s CEO Erkki Pekkarinen.
Almost 37 million people live with HIV worldwide today, and over 2 million new infections are diagnosed each year. Despite the many advances in the treatment and prevention of HIV made over the past 30 years, the development of an effective HIV vaccine has remained unachievable.
Finnish FIT Biotech Oy is part of the European HIV Vaccine Alliance (EHVA), a five-year project funded by the European Union's Horizon 2020 Research and Innovation Framework Program and the Swiss government, to develop an effective vaccine for the prevention of HIV infection and AIDS.
In November 2018, EHVA has started clinical trials with FIT Biotech Oy’s therapeutic HIV vaccine, FIT-06, by initiating the recruitment of participants. The clinical study will evaluate a novel combination therapy including FIT-06 vaccine in HIV-positive volunteers in six European countries. FIT-06 is used as the priming vaccine to induce immune responses. The final study results are planned to become available in 2021.
The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. The international alliance, which includes academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America, will work to discover and progress novel vaccine candidates (www.ehv-a.eu).